Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches
Executive Summary
After DEA scheduling, Reyvow will be available at pharmacies soon with a list price of $640 for eight tablets. Allergan confirmed that its drug is at pharmacies and prescriptions are being filled.
You may also be interested in...
Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks
With a US FDA endorsement, the drug – soon to join AbbVie’s portfolio under the companies’ $63bn merger – is the first oral option in its class and the first CGRP inhibitor approved to stop a migraine when it strikes.
Need a specific report? 1000+ reports available
Buy Reports